- Home
- CYRX vs VNDA Comparison
CYRX vs VNDA Comparison
Compare CYRX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- VNDA
- Stock Information
- Founded
- CYRX 1999
- VNDA 2002
- Country
- CYRX United States
- VNDA United States
- Employees
- CYRX N/A
- VNDA N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- VNDA Health Care
- Exchange
- CYRX Nasdaq
- VNDA Nasdaq
- Market Cap
- CYRX 405.4M
- VNDA 302.5M
- IPO Year
- CYRX N/A
- VNDA 2006
- Fundamental
- Price
- CYRX $8.17
- VNDA $5.02
- Analyst Decision
- CYRX Buy
- VNDA Buy
- Analyst Count
- CYRX 6
- VNDA 1
- Target Price
- CYRX $12.50
- VNDA $13.00
- AVG Volume (30 Days)
- CYRX 594.0K
- VNDA 477.8K
- Earning Date
- CYRX 08-06-2024
- VNDA 07-31-2024
- Dividend Yield
- CYRX N/A
- VNDA N/A
- EPS Growth
- CYRX N/A
- VNDA N/A
- EPS
- CYRX N/A
- VNDA N/A
- Revenue
- CYRX $225,606,000.00
- VNDA $182,022,000.00
- Revenue This Year
- CYRX $1.10
- VNDA $6.70
- Revenue Next Year
- CYRX $8.93
- VNDA $51.03
- P/E Ratio
- CYRX N/A
- VNDA N/A
- Revenue Growth
- CYRX N/A
- VNDA N/A
- 52 Week Low
- CYRX $5.32
- VNDA $3.30
- 52 Week High
- CYRX $20.11
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- CYRX 44.03
- VNDA 36.43
- Support Level
- CYRX $8.59
- VNDA $4.96
- Resistance Level
- CYRX $9.36
- VNDA $5.13
- Average True Range (ATR)
- CYRX 0.51
- VNDA 0.17
- MACD
- CYRX -0.09
- VNDA -0.01
- Stochastic Oscillator
- CYRX 8.31
- VNDA 17.07
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.